physician's choice chemotherapy
1 product
1 abstract
6 targets
Target
PD-L1Target
DNATarget
microtubulesTarget
TOP1Target
ribonucleotide reductaseTarget
PD-1Abstract
Cost-effectiveness of trastuzumab deruxtecan in HER2 low metastatic breast cancer.Org: Stanford Hospital & Clinics, Department of Management Science and Engineering, Stanford University School of Medicine, Department of Health Policy,